Revvity Signals Banner Ad (Nov-Dec)

EDITORIAL SECTION

KNOWLEDGE BANK

  • Articles

    How Single Use Technologies Are Changing Biopharmaceutical Production

    For most of the biopharmaceutical industrys history a manufacturing plant was defined by its steel Gleaming tanks fixed piping and miles of welded lines were built to last for decades cleaned and sterilized between every batch and validated at great expense before a single dose left the building That model delivered the first generation of biologics but it was designed for a world of few products...

  • Techno Trends

    Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment

    Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment

TOP ARTICLES

  • 1

    Challenges and Compliance in Pharma HCP Communication

    Kate Williamson

    The communication between Pharma HCP is necessary to provide clinical insights and guarantee pharmaceutical compliance. This article will reveal the ethical issues, regulatory policies, and ethical pr...

press releasesRead more...

Kamau Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Nula-cel, a Gene-Corrected Stem Cell Therapy for Sickle Cell Disease

Kamau Therapeutics a clinicalstage company creating medicines that endure by precisely engineering patients own blood stem cells today announced that the US Food and Drug Administration FDA has granted Regenerative Medicine

Resero Analytics Launches TurboLIMS to Accelerate Nonclinical Studies

Resero Analytics today launched TurboLIMS a cloudbased laboratory information management system for GLP and nonGLP studies in toxicology pharmacology pharmacokinetics and toxicokinetics TurboLIMS is a core component of Reseros TurboPlatform

Takara Bio USA Collaborates with the Allen Institute to Enable Spatial Mapping Across Broader Brain Regions with the Trekker® Spatial Biology Platform

Takara Bio USA Inc a wholly owned subsidiary of Takara Bio Inc Takara Bio today announced a significant expansion of its Trekker SingleCell Spatial Mapping Kits with the introduction of largeformat tiles

Argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities

Argenx the immunology innovation company today announced a definitive agreement to acquire Unnatural Products Inc UNP adding a macrocyclic peptide discovery engine to its immunology innovation capabilities argenx which already holds a minority stake in UNP will acquire all remaining shares in a tran...

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

LATEST NEWSRead more...

Cyclarity Therapeutics Receives FDA Clearance for UDP-003 Clinical Trial Application in the US

Cyclarity Therapeutics Inc has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UDP enabling the company to expand its atherosclerosis clinical development programme into the United States

Santhera Signs Distribution Agreement with SteinCares for AGAMREE in 31 Latin American and Caribbean Countries

Cyclarity Therapeutics Inc has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UDP enabling the company to expand its atherosclerosis clinical development programme into the United States

Oncolytics Biotech Signs Clinical Supply Agreement to Evaluate Pelareorep with LOQTORZI in Anal Cancer

Oncolytics Biotech Inc Nasdaq ONCY a clinicalstage immunotherapy company developing pelareorep has signed a clinical supply agreement with Coherus Oncology to evaluate pelareorep in combination with LOQTORZI toripalimabtpzi in patients with squamous cell anal carcinoma SCAC

MD Logic Health and Blu Vitals Launch Nine-Form Magnesium Supplement Mag 9+

MD Logic Health has partnered with Blu Vitals to launch Mag the first product developed through their collaboration The new magnesium supplement combines nine forms of magnesium with four additional nutrients in a daily formula designed to support energy production muscle and nerve function and bon...

PharmAla Biotech Signs Supply and Data Agreement with Aalborg University Hospital for Danish Randomized Trial of MDMA-Assisted Treatment for Service-Related PTSD

PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed a Project Supply Agreement the Agreement with the North Denmark Region

PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product

PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed an agreement with Corealis Pharma Inc Corealis a GMPcompliant contract development